STAT

He wants to sell you a $300 ‘fasting diet’ to prolong your life. It might not be as crazy as it sounds

Biochemist Valter Longo is promoting a 'fasting diet' that he claims can improve health and maybe prolong life. Here's what the science says.

LOS ANGELES — He knows he sounds like a snake-oil salesman.

It’s not every day, after all, that a tenured professor at a prestigious university starts peddling a mail-order diet to melt away belly fat, rejuvenate worn-out cells, prevent diseases ranging from diabetes to cancer — and, for good measure, turn back the clock on aging.

But biochemist Valter Longo is convinced that science is on his side.

Longo has spent decades studying aging in yeast cells and lab mice. He now believes he’s developed a diet that may boost longevity — by mimicking the effect of periodic fasting. So he’s packed precise quantities of kale chips, quinoa soup, hibiscus tea, and other custom concoctions into boxes that go for $300 a pop.

Longo’s ProLon diet (it stands for “pro-longevity,” he says, and not “Professor Longo”) reflects a growing interest in episodic fasting, which has been touted by celebrities such as Jimmy Kimmel and Benedict Cumberbatch and in best-selling books like “The Alternate-Day Diet.” His approach stands out because he insists he can use certain combinations of nutrients to trick the body into thinking it’s fasting without actually being on a punishing, water-only diet.

Read more: Kale crackers and hibiscus tea: My five days on a ‘fasting diet’

Intrigued, STAT reviewed dozens of scientific studies and talked to a half-dozen aging and nutrition experts about fasting in general and ProLon in particular. We visited Longo’s lab at the University of Southern California’s Longevity Institute, where slender black and white rodents pass their days in clear plastic boxes labeled “DO NOT FEED.” We even tried Longo’s diet for one long and rather hungry week.

Our conclusion? Fasting does appear to boost health — , and preliminary evidence suggests it might do so in humans as well, at least in the

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

Related Books & Audiobooks